Dr. Kan graduated from National Tsinghua University in Taiwan and completed post-doctoral research at Tsukuba University in Japan. He served as Associate Director of the Taiwan Liposomal Company, a Researcher at the Biomedical Engineering Center of the Industrial Technology Research Institute, and a Researcher at Tsukuba University in Japan. He has worked in the pharmaceutical industry for more than 20 years, focused on pharmaceutical formulation technology and product development, published over 50 papers and more than 10 patents related to drug delivery, some of which have been used in clinical products. In addition, he has led the development of several new formulation-based drug projects and completed filing and listing of IND, BioIND, and ANDA products in Taiwan, China, the United States, Japan, and Europe. He is now the President of Pharmosa.
Mr. Pao has over 30 years of experience in pharmaceutical manufacturing operations and supply chain management. Prior to joining Pharmosa, he served for Taiwan Liposome Company (TLC) and held positions as manufacturing development senior director, where he was responsible for outsourcing management, CMC operations, manufacturing transfer and purchasing activities. Before the Taiwan Liposome Company, Mr. Pao served for Taiwan Yamanouchi Pharmaceutical (now Astellas Pharma). During his time with Yamanouchi, Mr. Pao held various positions including technical services, QA/QC manager, responsible for validation activities and GMP plant management. After that he served as a manager of regulatory affairs in charge of drug registration. Mr. Pao holds a bachelor degree from the Department of Pharmacy, Chia Nan University of Pharmacy & Science. He also has a pharmacist certificate.
Ms. Lin received an MBA degree from University of California, Riverside, USA. Ms. Lin has more than 3 decades of experiences in management and administration for start-ups, bio-tech and public companies covering corporate governance and compliances, ESG, HR, international contracts, taxation, fund raising, strategic cross-border subsidiaries setups, organizational behaviors, etc. Prior to joining Pharmosa, she served as VP of Administration in TLC for more than 15 years, from pre-IPO to public stages. She also worked in California-based technology firms and CPA firm in earlier years of career. Ms. Lin is recognized as a Certified Public Accountant in California, USA.
Ms. Yang graduated from the Department of Accountancy and the Graduate Institute of Finance from National Cheng Kung University. She brings Pharmosa 15 years of experience in financial and accounting, capital market fundraising and M&A. Prior to joining Pharmosa, Ms. Yang was Senior Vice President of the Investment Banking Department at KGI Securities Co. Ltd. and led 12 IPO projects, 14 SPO projects, 7 M&A projects, and pre-IPO consultation. She also participated in TaiGen Biotech’s (TPEx: 4157) US$1.1 billion initial public offering on the Taipei Exchange. Ms. Yang has expertise in investment structure planning, joint ventures, corporate reorganization, corporate governance, auditing and internal control, personnel optimization, business development, and strategic planning. Ms. Yang started her career with KPMG as a financial auditor.
Mr. Lu holds a master's degree from the Department of Pharmacology and Toxicology, Tzu Chi University and has over 15 years' experience in new drug development. Mr. Lu was Vice President of Product Development in TWi Biotechnology, Inc. In the role of Vice President, Mr. Lu managed TWi leading project development programs in the areas of rare disease and skin inflammatory disorders, managed and accomplished IND filings, orphan drug designation approval from US FDA/TFDA and patent application. He also has a pharmacist certificate.
Dr. Liang graduated from the Chemical Engineer Department of National Tsinghua University in Taiwan in 2005. Before joining Pharmosa, he served as Senior Director of the Manufacturing & Technology Division of TaiMed Biologics and as Senior Researcher of Industrial Technology Research Institute. When he worked in TaiMed, he was responsible for the tech transfer, process development and scale-up, GMP manufacturing, and CMC package preparation and submission of nanomedicine and antibody drugs. He participated in the development and commercialization of the first anti-HIV antibody in the US and EU as well as the regulatory submission of post-approval changes and the manufacturing site change. He also took charge of the developmental strategies of products in different stages of clinical trials.
Ms. Chen obtained a Ph.D. from the Department of Chemical Engineering at National Tsinghua University, specializing in the research and design of dosage pharmaceuticals. She previously worked in Taiwan Liposome Company as a researcher for developing dosage pharmaceuticals, during which she participated in the research and development of new anti-cancer drugs. At Pharmosa Biopharm, Ms. Chen was mainly responsible for the development of combination products for trial drugs and medical devices, as well as the management of relevant patents. Ms. Chen currently has obtained more than 10 domestic and foreign patents, and also has experience in analytical methods, development of mass production processes, and CMO technology transfer.
Ms. Chuang was graduated from the Traditional Medicine Institute at Yang Ming Chiao Tung University. Her expertise lies in clinical trial planning and execution, CRO selection and project management. With over 15 years of experience in clinical relevant positions at international pharmaceutical companies, biotech companies, and CROs. She was responsible for project management and execution in Phase I-IV clinical trials, including clinical trial strategy development and planning across various therapeutic areas, CRO management, and participation in IRB audits and TFDA inspections. She also had experiences in conducting clinical trials with combination products. Currently, she serves as the Associate Director at Pharmosa, leading the key products into Phase III clinical trials, planning clinical development on new indications, and strategizing, planning, managing, and executing international clinical trials.She was a Clinical Manager at BioGend Therapeutics Co., Ltd., Clinical Project Manager at Taiwan Liposome Company, Ltd., and Clinical Manager at Novartis Taiwan Co., Ltd.